Darifenacin Hydrobromide

CHEMBL1200935 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

507.5 g/mol

LogP

—

Phase

4

The hydrobromide salt form of darifenacin, an M3-selective antimuscarinic drug taken orally once daily for overactive bladder symptoms. The extended-release formulation provides consistent drug levels throughout the day.

Moleküler Ağırlık

507,5000 g/mol

TPSA

55,60 Å²

Terapötik Alanlar

Parkinson's Disease Multiple Sclerosis

Etki Mekanizması

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

Br.NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(CCc2ccc3c(c2)CCO3)C1

InChI

InChI=1S/C28H30N2O2.BrH/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26;/h1-12,19,25H,13-18,20H2,(H2,29,31);1H/t25-;/m1./s1

Molecular Formula

C28H31BrN2O2

HBD / HBA

2 / 3

Döndürülebilir Bağlar

7

Ağır Atomlar

33

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

The hydrobromide salt form of darifenacin, an M3-selective antimuscarinic drug taken orally once daily for overactive bladder symptoms. The extended-release formulation provides consistent drug levels throughout the day.

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Yes, Darifenacin Hydrobromide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200935. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 444030. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Darifenacin Hydrobromide PillFYI'da

Yapı

Hızlı Veriler

Formül: C28H31BrN2O2
Eş Anlamlılar: 2

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Darifenacin Hydrobromide

Terapötik Alanlar

Etki Mekanizması

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

Cite this structure

Embed this structure

No targets recorded

No interactions recorded

No side effects recorded

Sıkça Sorulan Sorular

References & Data Sources

Embed This Widget